1. Please define ADRs and ADEs and the difference between the two concepts. As I understand: (do not cite, find appropriate references please) an "Adverse Drug Reaction is a reaction which is mentioned for specific drug in the prescription explanation given by drug manufacturer, in other words it is an objective adverse reaction evidence-based on the findings from the clinical trials". "Adverse Drug Event is a side effect which was revealed after usage the drug and is reported by the patient or the doctor who faced with this event in his personal experience" 2. Please change to British English (multicentre, not multicentre, for example). 3. Including patients from the "floating population" is a strength of the study, as selection bias would be introduced otherwise. However, the term needs to be defined and explained since not all readers are familiar with this concept, that is common in China. 4 . Perhaps the first exclusion criteria could be explained a bit more thorough? "having a psychiatric illness" is clear, but "requiring the incorporation of a questionnaire investigation" is not so clear. Does it have to do with the severity of the psychiatric illness? Please clarify. 5. Regarding the second exclusion criteria, I suggest …with a lifeexpectancy shorter than 6 months" for more appropriate English. 6. "Treatment adherence" is preferable to "treatment compliance", since it's regarded less derogatory. According to the 2013 WHO definitions, treatment interruption for more than 2 months is defined as "Loss to follow-up". 7. Are patients excluded if they miss one or all the scheduled laboratory tests in the first two months? A suggestion is to provide more details. 8. Suggest "ADR classification" instead of "ADR judgement". 9. Will Bedaquiline be used for MDR-TB? Following the recently changed WHO recommendation, perhaps regular ECGs and cardiac ADRs might need to be added? 10. "When all TB patients finish treatment, the local supervising doctors will comprehensively judge the patient's treatment outcomes according to their symptoms and signs, various clinical examinations, drug use, etc., and record them on the management card of every patient." Please make sure that definitions of treatment outcome follow the latest definitions by the World Health Organization, to be able to compare results with other international studies. 11. Regarding the number of included patients, perhaps information about how many TB patients are normally treated in the four included hospitals could be added. How much attrition due to patients not being willing to join have you assumed? Important information to judge whether the study is likely to be able to include enough patients during the study period. 12. Statistical analysis. Consider performing Cox regression analysis to also investigate time to event data, interesting information for ADRs. 13. The genetic analyses are not described in detail. It is Important that all genetic analyses are prespecified and included in the informed consent so patients know what kind of genetic analysis are being performed and why. 14. "Most ADRs induced by anti-TB drugs occur within the first two months of treatment [6, 42] General comments This is an important study which attempts to provide answers regarding the occurrence of ADRs in a home-based setting. The strength of the design is the 'natural setting' and the incorporation of genetic testing, which has lacked in many published studies.
Specific comments
Q1. In the Introduction, page 4, line 26-28: please revise the sentence to read in part ' …, arthralgia, and neurological disorders.' Delete "and so on". A1: We would like to thank the referee for the useful comments. We have revised the manuscript.
Q2. study design: It is stated that a sample size of 3200 will be targeted. However, the methods section also states that all eligible patients will be recruited. This sounds contradictory. The authors can consider providing a little bit more details on the study setting of the four institutions in terms of how many TB patients are treated in these institutions: how many TB patients are treated at any one point in time, and how many new patients are initiated per year. This will contextualize and reconcile the sample size calculation and the statement about recruiting all eligible patients in the study A2: We would like to thank the referee for the useful comments. Because of our negligence, we did not express clearly. As we described in the manuscript, only newly diagnosed TB patients between January 2019 and December 2020 will be included in present study. We set the target sample size to 3200 newly diagnosed TB patients. Based on our previous ADACS cohort [1] , and setting the exclusion rate to 2.4% and the participation rate of eligible subjects to 71.2% [2] , at least 4600 newly diagnosed TB patients will be needed within two years. According to the number of newly diagnosed TB patients in each hospital per year (600 patients per hospital), the total number of TB patients in four hospitals is almost 2400 per year, which fully meets the sample size requirement in two years. So, the subjects recruited should be potential eligible patients, not all patients, because 71.2% of patients were unwilling to participate in the study [2] . We have modified this error here. Additionally, we also modified the effect size of odds ratio (OR) to make it more reasonable (the original value is a bit large). We have revised the description in Sample size calculation section.
Q3. Methods, page 5, line 53-55: The withdrawal of 'patients who develop diseases that meet exclusion criteria after enrollment" needs clarification. At what stage after enrollment will these patients be withdrawn? I assume it is before patients start receiving TB treatment. Withdrawal of patients who develop psychiatric disorders or liver disorders after they initiate treatment will introduce bias. Therefore, it is important to state the specific time at which development of the diseases that meet the exclusion criteria will lead to patient withdrawal from the study. A3: We would like to thank the referee for the useful comments. Because of our negligence, we did not express clearly. This refers to the withdrawal of the study after the patient received anti-TB treatment. These patients are mainly suffering from serious diseases that prevent them from continuing anti-TB treatment, and not subjectively unwilling to continue treatment. However, it does not include patients who are unable to continue treatment because of adverse drug reactions. Otherwise, it will introduce bias. We have revised the Withdrawal criteria to make it clearer ((3) developing serious diseases that prevent them from continuing anti-TB treatment).
Q4. Page 5, line 1: The withdrawal of patients whose death is not caused by anti-TB drug-induced ADRs needs clarification. The first objective includes clinical outcomes of TB treatment. Will patients who die from TB be withdrawn? This may bias the outcomes related to treatment since deaths could indicate a poor response to the drugs, which could be due to genetic factors or other factors that the protocol is trying to elucidate. A4: We would like to thank the referee for the useful comments. Indeed, the withdrawal of patients who die from TB would bias the outcomes related to treatment. In China, unless there are other exact causes of death, sometimes it is difficult to distinguish whether the patient died of TB or other combined diseases. If these TB patients were not cured, they would be presumed to die of TB when they died. However, in reality, they may also die of other diseases. According to your suggestion, we will include patients who died of TB. Sensitivity analysis (with and without this part of patients) could be performed when the outcomes related to treatment are analyzed. We have revised the Withdrawal criteria to make it clearer ((5) death that is not caused by TB or anti-TB drug-induced ADRs).
Q5. It is stated that a matched nested case-control study will be used to evaluate the risk factors for the development of ADRs. What are the variables that will be used to match the cases and the controls? These need to be specified in the protocol. The exact definitions for cases and controls should also be provided. The ratio of the cases and controls should also be specified in the protocol before the analysis is conducted. A5: We would like to thank the referee for the useful comments. Because of our negligence, we did not express clearly. Unmatched nested case-control study will be used to evaluate general the risk factors for the development of ADRs (including anti-TB drug-induced hepatotoxicity (ATDH)). Patients who fulfilled the ATDH criteria will be assigned to the case group, whereas controls will be selected from those with sustained normal liver function through the whole therapy. Furthermore, matched nested case-control study will be used to explore the role of genetic polymorphisms in susceptibility to ATDH. For each ATDH case, two controls will be selected randomly and matched for the place of sample collection, age (within 5 years), sex and treatment history. We have revised the Data analysis plan to make it clearer. Q6. Page 8; All statements in the data analysis plan should be in future tense. A6: We would like to thank the referee for the useful comments and have revised the manuscript. Q1. Please define ADRs and ADEs and the difference between the two concepts. As I understand: (do not cite, find appropriate references please) an "Adverse Drug Reaction is a reaction which is mentioned for specific drug in the prescription explanation given by drug manufacturer, in other words it is an objective adverse reaction evidence-based on the findings from the clinical trials". "Adverse Drug Event is a side effect which was revealed after usage the drug and is reported by the patient or the doctor who faced with this event in his personal experience". A1: We would like to thank the referee for the useful comments. Because of our negligence, we did not give a clear definition. According to WHO, adverse drug event (ADE) is defined as any untoward medical occurrence that may appear during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with the treatment [1] , and an adverse drug reaction (ADR) is any response to a drug that is noxious and unintended and that occurs at doses normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function [2] . We have revised the manuscript and added the definitions. Q2. Please change to British English (multicentre, not multicentre, for example).
A2: We would like to thank the referee for the useful comments and have revised the manuscript.
Q3. Including patients from the "floating population" is a strength of the study, as selection bias would be introduced otherwise. However, the term needs to be defined and explained since not all readers are familiar with this concept, that is common in China.
Q4. Perhaps the first exclusion criteria could be explained a bit more thorough? "having a psychiatric illness" is clear, but "requiring the incorporation of a questionnaire investigation" is not so clear. Does it have to do with the severity of the psychiatric illness? Please clarify. A4: We would like to thank the referee for the useful comments. Because of our negligence, we did not express clearly. In fact, this mainly means that patients with psychiatric illness cannot self-record the signs and/or symptoms of adverse drug reactions during the anti-tuberculosis treatment. So, we have revised the first exclusion criteria ((1) having a psychiatric disease and unable to fill out the selfrecorded diaries during the anti-TB treatment).
Q5. Regarding the second exclusion criteria, I suggest …with a life-expectancy shorter than 6 months" for more appropriate English. A5: We would like to thank the referee for the useful comments and have revised the manuscript. Q6. "Treatment adherence" is preferable to "treatment compliance", since it's regarded less derogatory. According to the 2013 WHO definitions, treatment interruption for more than 2 months is defined as "Loss to follow-up". A6: We would like to thank the referee for the useful comments and have revised the manuscript.
Q7. Are patients excluded if they miss one or all the scheduled laboratory tests in the first two months? A suggestion is to provide more details. A7: We would like to thank the referee for the useful comments. This refers to patients without all the scheduled laboratory tests in the first two months, which makes it impossible to judge the occurrence of liver injury. We have revised the manuscript.
Q8. Suggest "ADR classification" instead of "ADR judgement". A8: We would like to thank the referee for the useful comments and have revised the manuscript.
Q9. Will Bedaquiline be used for MDR-TB? Following the recently changed WHO recommendation, perhaps regular ECGs and cardiac ADRs might need to be added? Q11. Regarding the number of included patients, perhaps information about how many TB patients are normally treated in the four included hospitals could be added. How much attrition due to patients not being willing to join have you assumed? Important information to judge whether the study is likely to be able to include enough patients during the study period.
